{"id":26243,"date":"2025-02-11T11:05:39","date_gmt":"2025-02-11T03:05:39","guid":{"rendered":"https:\/\/flcube.com\/?p=26243"},"modified":"2025-02-11T11:05:41","modified_gmt":"2025-02-11T03:05:41","slug":"r-nanoablation-raises-usd-13-7m-in-series-b-to-advance-nanosecond-ablation-tech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=26243","title":{"rendered":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech"},"content":{"rendered":"\n<p>Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.<\/p>\n\n\n\n<p><strong>Funding Details<\/strong><br>Proceeds will support R-Nanoablation&#8217;s pipeline, including devices for tumors, atrial fibrillation, and chronic encephalopathy. The company plans to leverage its ultra-high voltage, ultra-short nsPEF technology, which offers tissue selectivity and rapid energy release, positioning it as a next-gen ablation solution.<\/p>\n\n\n\n<p><strong>Company Profile<\/strong><br>Founded in 2014, R-Nanoablation has multiple products in development, with some holding fast-track status in China. Its nsPEF platform is designed to improve efficacy and safety in minimally invasive treatments, targeting unmet needs in oncology and cardiology.<\/p>\n\n\n\n<p><strong>Strategic Outlook<\/strong><br>The Series B+ funding will help R-Nanoablation scale clinical trials and prepare for regulatory submissions. The company aims to establish its nsPEF technology as a standard in ablation therapies, with plans to expand globally.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD&#8230;<\/p>\n","protected":false},"author":1,"featured_media":26245,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,3611],"class_list":["post-26243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-r-nanoablation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=26243\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech\" \/>\n<meta property=\"og:description\" content=\"Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=26243\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-11T03:05:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-11T03:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech\",\"datePublished\":\"2025-02-11T03:05:39+00:00\",\"dateModified\":\"2025-02-11T03:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243\"},\"wordCount\":179,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/1101-png.avif\",\"keywords\":[\"Finance\",\"R-Nanoablation\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26243#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=26243\",\"name\":\"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/1101-png.avif\",\"datePublished\":\"2025-02-11T03:05:39+00:00\",\"dateModified\":\"2025-02-11T03:05:41+00:00\",\"description\":\"Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26243\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/1101-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/1101-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26243#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=26243","og_locale":"en_US","og_type":"article","og_title":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech","og_description":"Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.","og_url":"https:\/\/flcube.com\/?p=26243","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-02-11T03:05:39+00:00","article_modified_time":"2025-02-11T03:05:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=26243#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=26243"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech","datePublished":"2025-02-11T03:05:39+00:00","dateModified":"2025-02-11T03:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=26243"},"wordCount":179,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=26243#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif","keywords":["Finance","R-Nanoablation"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=26243#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=26243","url":"https:\/\/flcube.com\/?p=26243","name":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=26243#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=26243#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif","datePublished":"2025-02-11T03:05:39+00:00","dateModified":"2025-02-11T03:05:41+00:00","description":"Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=26243#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=26243"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=26243#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif","width":1080,"height":608,"caption":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=26243#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/1101-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26243"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26243\/revisions"}],"predecessor-version":[{"id":26246,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26243\/revisions\/26246"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/26245"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}